Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06044857 · ClinicalTrials.gov registry record · Phase 1
PSMA PET Response Guided SabR in High Risk Pca
A Phase 1 study of Prostate Adenocarcinoma, sponsored by University of Texas Southwestern Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT06044857: Recruiting Phase 1 study of Prostate Adenocarcinoma, sponsored by University of Texas Southwestern Medical Center.
NCT06044857 is a Phase 1 study of Prostate Adenocarcinoma that is actively recruiting participants, run by University of Texas Southwestern Medical Center. The registered enrollment target is 20 participants, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (91% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06044857, a Phase 1 study of Prostate Adenocarcinoma, is actively recruiting participants, sponsored by University of Texas Southwestern Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of dominant intra-prostatic lesion tumor boost dose
Primary Outcome
This study primarily evaluates volume reduction of initial target PSMA-avid dominant intra-prostatic disease after neoadjuvant ADT and during SAbR in differing spacing regimens of SAbR. Metrics include percent reduction in volume at 3 months of therapy vs initial disease extent of intra-prostatic dominant lesion as identified by PSMA PET.
Conditions Studied
Interventions
- DRUG 68-Ga PSMA11
Study Locations (2)
Texas
- University of Texas Southwestern Medical Center - Dallas
- UT Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-03-07 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What NCT06044857 shows while recruiting
NCT06044857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 218-participant average among 99 other Prostate Adenocarcinoma trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Prostate Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which 68-Ga PSMA11 is the first listed.
NCT06044857 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06044857 about?
NCT06044857 is a clinical study titled "PSMA PET Response Guided SabR in High Risk Pca". Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of dominant intra-prostatic lesion tumor boost dose
What is the current status of trial NCT06044857?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-03-07. Estimated completion is 2026-11.
What conditions does trial NCT06044857 study?
This clinical trial studies the following conditions: Prostate Adenocarcinoma.
What interventions are being tested in trial NCT06044857?
The interventions under investigation include: 68-Ga PSMA11 (DRUG).
Who is sponsoring clinical trial NCT06044857?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06044857 being conducted?
This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06044857's enrollment target sits among peer trials
20 85th of 99 higher than 12 of 99 other Prostate Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RECRUITING · Phase 1
-
Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
RECRUITING · Phase 1
-
Enzalutamide Implants (Enolen) in Patients With Prostate Cancer
RECRUITING · Phase 1
-
A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer
RECRUITING · Phase 1
-
Bicalutamide Implants (Biolen) With Radiation Therapy in Patients With Localized Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI